Published on 21 Feb 2024 on Simply Wall St. via Yahoo Finance
Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m
The recent price decline of 73% in RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) stock may have disappointed insiders who bought US$97.6k worth of shares at an average price of US$19.52 in the past 12 months. Insiders invest with the hopes of seeing their money grow in value over time. However, as a result of recent losses, their initial investment is now only worth US$34.4k, which is not what they expected.
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
See our latest analysis for RAPT Therapeutics